Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Retatrutide: what it is studied alongside

Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist. This page maps the compounds, pathways, tissues and models it has been studied alongside in published research, and flags where the evidence is ani

peptides-pro Editorial

Retatrutide, also known by the development code LY3437943, is an investigational triple receptor agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors [1][3]. It is being studied for chronic weight management and for type 2 diabetes mellitus, and it has no established role in type 1 diabetes mellitus [1]. The evidence block used for this page does not supply a sequence, molecular formula or molecular weight for the compound, so none is stated here. Where the literature compares retatrutide with other agents, the comparators are typically semaglutide and tirzepatide, and the work centres on the incretin receptor family and the metabolic, renal and hepatic pathways downstream of it [2].

Because retatrutide acts at three receptors rather than one or two, studies tend to place it alongside compounds that act at one or two of the same receptors, and alongside pathway readouts such as PI3K-AKT, NF-κB, PPAR, HOMA-IR and clamp-derived indices of insulin secretion and sensitivity [2][4][8]. The sections below set out what has been studied alongside what, in which model, and whether the finding is animal-only, in vitro, or from a registered human trial.

Research Studies

Retatrutide and semaglutide or tirzepatide in renal fibrosis models

A comparative study evaluated semaglutide, tirzepatide and retatrutide for anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis, using HK-2 cells together with murine unilateral ureteral obstruction (UUO) and aging models [2]. Integrating in vivo and in vitro data showed model- and drug-specific patterns of action among the three agents [2]. In the UUO model, semaglutide effects were associated with PI3K-AKT inhibition, tirzepatide effects with PI3K-AKT inhibition plus PPAR pathway activation, and retatrutide effects with concurrent inhibition of both PI3K-AKT and NF-κB pathways [2]. This is a preclinical comparison; the renal findings are animal and cell-culture based, not human outcome data.

CompoundReceptor profilePathway association reported in the UUO model
SemaglutideGLP-1 receptor agonistPI3K-AKT inhibition [2]
TirzepatideGIP/GLP-1 dual agonistPI3K-AKT inhibition and PPAR pathway activation [2]
RetatrutideGIP/GLP-1/glucagon triple agonistConcurrent inhibition of PI3K-AKT and NF-κB [2]

Retatrutide and diet-induced obese MASH mouse and hamster models

In diet-induced obese MASH mouse and hamster models, retatrutide was evaluated for efficacy as a triple glucagon, GIP and GLP-1 receptor agonist [4]. In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), reduced both fat and lean mass, and reduced food and water intake during the first days of treatment, while energy expenditure was not altered significantly [4]. Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides and total cholesterol content [4]. In hamsters, retatrutide altered — the evidence block truncates the hamster result, so no further detail is reported here. These are preclinical models; the findings are animal-only.

Retatrutide and hypoglycemia recovery in type 2 diabetes

A registered study measures the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during a hypoglycemic clamp in participants with type 2 diabetes mellitus following 16 weeks of treatment [7]. This is a human trial design; the evidence block gives the objective and duration, not results.

Retatrutide and insulin secretion and sensitivity in type 2 diabetes

A separate registered study compares the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment in adult participants with type 2 diabetes mellitus [8]. The primary objective is a clamp-derived measure of insulin secretion and sensitivity; again, the evidence block supplies the design, not outcomes.

Retatrutide and body weight reduction in obesity or overweight

A registered study evaluates the efficacy and safety of retatrutide compared with placebo for body weight reduction in participants with obesity or overweight; participation lasts about 65 weeks and may include about 18 visits [6]. A further registered study investigates the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight, with participation lasting about 113 weeks [5]. Both are human trial designs; no efficacy results are given in the evidence block.

Retatrutide and pre-approval expanded access in severe obesity

A pre-approval single-patient expanded access programme provides retatrutide (LY3437943) for adults with severe obesity, defined as a body mass index ≥35 kg/m² with at least two serious or life-threatening obesity-related complications, who are refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine [3]. This is an access programme, not a controlled comparison, and it is described here as a study setting rather than an outcome.

Retatrutide and cardiovascular risk biomarkers in adults with obesity, with or without type 2 diabetes

In a post hoc analysis of phase 2 trials, lipoprotein and inflammatory biomarkers were assessed in adults with obesity or overweight, with or without type 2 diabetes, to characterise the effects of retatrutide on cardiometabolic risk [10]. The analysis drew on data from two randomised, double-blind trials [10]. This is a human biomarker analysis; the evidence block does not give the numerical results, so none are reported here.

Retatrutide and diabetic rats' cognition

A study examined retatrutide effects on cognition in diabetic rats [12]. This is an animal model; the evidence block does not supply the direction or magnitude of the effect, so no result is stated here.

Retatrutide and product composition and labelling accuracy

A study examined the composition and labelling accuracy of products sold as retatrutide in Australia [9]. This is a product-quality investigation rather than a pharmacological comparison; it is reported here because it bears on what a given sample labelled retatrutide may actually contain.

Retatrutide and online-sourced use in type 1 diabetes with concurrent infection

A case report described a man in his mid-30s with longstanding type 1 diabetes mellitus who developed complicating impending diabetic ketoacidosis in the setting of concurrent Shigella gastroenteritis, in the context of online-sourced retatrutide use [1]. The report notes that growing public interest in incretin-based therapies for weight loss has been accompanied by increasing availability of research peptides purchasable online, that products may be used without medical assessment or counselling regarding adverse effects, sick-day management or appropriate follow-up, and that composition, purity and dosing accuracy may be uncertain [1]. Retatrutide has no established role in type 1 diabetes mellitus [1]. This is a single-patient clinical report, not a controlled study.

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research use only. We do not provide dosing or medical guidance, and nothing here is a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp